$27.99 / month – $237.99
Melanotan 2 (MT-2) is a cyclic heptapeptide analog of alpha-MSH that activates multiple melanocortin receptors. Research applications include skin pigmentation, sexual function enhancement, appetite regulation, and metabolic studies. 10mg vial, 99% purity.
Melanotan 2 (MT-2) represents one of the most extensively studied synthetic peptides in modern research. As a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH), this compound has captured scientific attention for its remarkable ability to activate multiple melanocortin receptors throughout the body. Unlike its linear counterpart Melanotan 1, MT-2’s unique cyclic structure provides enhanced stability, longer half-life, and broader receptor affinity, making it an invaluable tool for researchers exploring diverse physiological systems.
The story of Melanotan 2 begins in the 1980s at the University of Arizona, where researchers sought to develop a synthetic peptide that could stimulate melanogenesis without UV exposure. What emerged was a compound with far-reaching effects beyond simple skin pigmentation. Today, MT-2 serves as a critical research tool in studies examining skin health, sexual function, metabolic regulation, and appetite control. With over three decades of scientific investigation, Melanotan 2 has established itself as a cornerstone peptide in melanocortin receptor research.
PrymaLab’s Melanotan 2 10mg peptide represents the gold standard for research applications. Each vial contains 99% pure MT-2, verified through rigorous third-party testing using high-performance liquid chromatography (HPLC). This pharmaceutical-grade purity ensures consistent, reliable results across experimental protocols. Whether investigating skin pigmentation mechanisms, exploring sexual dysfunction pathways, or studying appetite regulation, researchers require the highest quality peptides to generate meaningful data. Our commitment to quality control and transparency makes PrymaLab the trusted source for serious peptide research.
Melanotan 2’s effectiveness stems from its sophisticated molecular architecture. This cyclic heptapeptide consists of seven amino acids arranged in a ring formation: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. The cyclic structure is created through a lactam bridge between the side-chain carboxyl group of aspartic acid at position 2 and the side-chain amino group of lysine at position 7. This ring formation provides several critical advantages over linear peptides.
First, the cyclic structure dramatically enhances metabolic stability. Linear peptides are vulnerable to enzymatic degradation by peptidases, which cleave peptide bonds and rapidly inactivate the compound. The ring formation in MT-2 protects against this degradation, extending the peptide’s half-life and allowing for less frequent dosing in research protocols. Studies indicate MT-2 maintains activity for 6-8 hours after administration, compared to 2-4 hours for linear analogs.
Second, the cyclic configuration optimizes receptor binding geometry. The constrained structure positions key amino acid residues in ideal spatial arrangements for melanocortin receptor interaction. This enhanced binding affinity translates to greater potency, with MT-2 demonstrating 1000-fold higher activity at melanocortin receptors compared to native α-MSH. Researchers can achieve desired effects with lower doses, reducing potential side effects while maintaining experimental efficacy.
Third, the specific amino acid substitutions in MT-2 broaden its receptor profile. The inclusion of D-phenylalanine (an unnatural D-amino acid) at position 4 further enhances stability while maintaining receptor affinity. The norleucine substitution at position 1 improves lipophilicity, facilitating cellular uptake and distribution. These modifications create a peptide that activates MC1R (melanogenesis), MC3R (energy homeostasis), and MC4R (sexual function) with remarkable efficiency.
The melanocortin receptor system represents one of the body’s most versatile signaling networks. These G-protein coupled receptors regulate diverse physiological processes through cyclic AMP (cAMP) second messenger pathways. When MT-2 binds to melanocortin receptors, it triggers conformational changes that activate adenylyl cyclase, increasing intracellular cAMP levels. This cascade amplifies the initial signal, producing robust cellular responses from relatively small peptide concentrations.
At MC1R, primarily expressed in melanocytes, MT-2 stimulates eumelanin synthesis through activation of tyrosinase and related enzymes. This produces the characteristic skin darkening observed in tanning research. At MC4R, concentrated in hypothalamic nuclei and spinal cord, MT-2 modulates sexual behavior and erectile function through complex neural pathways. At MC3R and MC4R, both involved in energy balance, the peptide influences appetite, metabolism, and body weight regulation. This multi-receptor activity makes MT-2 uniquely valuable for integrated physiological research.
Understanding the distinctions between Melanotan 2 and Melanotan 1 is essential for selecting the appropriate peptide for specific research objectives. While both compounds derive from α-MSH and share some overlapping effects, their structural differences create distinct pharmacological profiles that suit different experimental designs.
Structural Architecture: Melanotan 1 is a linear tetradecapeptide containing 13 amino acids in a straight chain configuration. This structure closely mimics native α-MSH, with strategic amino acid substitutions (norleucine at position 4, D-phenylalanine at position 7) that enhance stability and receptor affinity. In contrast, Melanotan 2 is a cyclic heptapeptide with only 7 amino acids arranged in a ring. This dramatic structural simplification actually increases potency and broadens receptor activity.
Receptor Selectivity: The most significant functional difference lies in receptor selectivity. Melanotan 1 demonstrates high selectivity for MC1R, the melanocortin receptor primarily responsible for melanogenesis. This selective activation makes MT-1 ideal for research focused exclusively on skin pigmentation, UV protection, and photodermatoses. The FDA has approved MT-1 (as Scenesse) for treating erythropoietic protoporphyria, validating its safety profile for MC1R-targeted applications.
Melanotan 2, conversely, activates multiple melanocortin receptors with relatively equal affinity. It stimulates MC1R for tanning effects, MC3R for metabolic regulation, and MC4R for sexual function. This broad receptor profile makes MT-2 the preferred choice for research examining integrated physiological responses, sexual dysfunction, appetite control, or multi-system effects. However, the broader activity also means more potential side effects, requiring careful protocol design.
Dosing Frequency: Pharmacokinetic differences influence dosing schedules. Melanotan 1’s linear structure results in faster enzymatic degradation, necessitating twice-daily injections in most research protocols (typically 1mg morning and evening). Melanotan 2’s cyclic structure provides enhanced stability, allowing once-daily dosing (0.25-2mg depending on application). For long-term studies, this dosing convenience can significantly reduce experimental burden and improve protocol compliance.
Effect Profile: While both peptides produce skin darkening, their additional effects differ markedly. Melanotan 1 research focuses primarily on photoprotection, with studies demonstrating 47% reduction in sunburn severity and improved UV tolerance in subjects with photosensitivity disorders. Side effects are generally mild, including nausea (19%), fatigue (6%), and localized injection site reactions.
Melanotan 2 produces more diverse effects reflecting its multi-receptor activity. Beyond tanning, research has documented significant impacts on sexual function, with 85% of subjects in erectile dysfunction studies reporting improved erections. MT-2 also demonstrates appetite suppression and potential weight loss effects through MC3R/MC4R pathways. However, this broader activity comes with more varied side effects, including nausea (41%), stretching/yawning (56%), spontaneous erections, and flushing.
Research Applications: Choose Melanotan 1 for studies requiring selective MC1R activation, particularly research on photodermatoses, UV protection mechanisms, or skin pigmentation pathways. The FDA approval and extensive safety data make MT-1 appropriate for translational research with potential clinical applications. Choose Melanotan 2 for investigations requiring multi-receptor activation, especially studies on sexual dysfunction, appetite regulation, metabolic effects, or integrated physiological responses. The broader activity profile makes MT-2 valuable for exploratory research and mechanism-of-action studies.
Safety Considerations: Both peptides require appropriate precautions, but their safety profiles differ. Melanotan 1 has undergone extensive Phase 3 clinical trials with up to 8 months of continuous administration, demonstrating favorable long-term safety. Melanotan 2 research has primarily involved shorter-term studies (2-4 weeks), with less data on extended use. Some case reports have linked prolonged MT-2 use combined with UV exposure to melanoma development, though causation remains unproven. Researchers should implement appropriate washout periods and avoid combining MT-2 with excessive UV exposure in experimental protocols.
Melanotan 2’s most established research application involves skin pigmentation and photoprotection. The peptide’s activation of MC1R in melanocytes triggers a cascade of events leading to increased melanin synthesis, the body’s natural defense against UV radiation. This mechanism has profound implications for understanding skin biology and developing interventions for photosensitivity disorders.
When MT-2 binds to MC1R on melanocyte cell surfaces, it initiates a signaling cascade through G-protein activation and cAMP production. Elevated cAMP levels activate protein kinase A (PKA), which phosphorylates and activates the transcription factor CREB (cAMP response element-binding protein). CREB then upregulates expression of microphthalmia-associated transcription factor (MITF), the master regulator of melanocyte function.
MITF increases expression of key melanogenic enzymes including tyrosinase, tyrosinase-related protein 1 (TRP-1), and tyrosinase-related protein 2 (TRP-2). Tyrosinase catalyzes the rate-limiting step in melanin synthesis, converting tyrosine to DOPA and subsequently to dopaquinone. These intermediates undergo further enzymatic modifications to produce eumelanin, the brown-black pigment that provides photoprotection, or pheomelanin, the red-yellow pigment associated with fair skin.
Research demonstrates that MT-2 preferentially stimulates eumelanin production over pheomelanin synthesis. Eumelanin provides superior UV protection through multiple mechanisms: it absorbs UV photons across a broad spectrum (200-400nm), dissipates absorbed energy as heat, and scavenges reactive oxygen species generated by UV exposure. Studies show that MT-2-induced tanning reduces sunburn severity by 47% and increases minimal erythema dose (MED) by 2-3 fold.
The tanning response to MT-2 follows a predictable time course. Initial pigmentation becomes visible within 3-5 days of daily administration, with progressive darkening over 10-14 days. Unlike UV-induced tanning, which requires repeated sun exposure and carries DNA damage risks, MT-2 produces pigmentation without UV exposure. This “sunless tanning” provides photoprotection before UV exposure occurs, offering a preventive rather than reactive approach to sun protection.
Importantly, MT-2-induced pigmentation differs qualitatively from UV-induced tanning. UV exposure triggers both immediate pigment darkening (IPD) through oxidation of existing melanin and delayed tanning (DT) through new melanin synthesis. MT-2 primarily stimulates new melanin production without the oxidative stress and DNA damage associated with UV exposure. This makes MT-2 an valuable tool for studying melanogenesis mechanisms independent of UV-induced cellular stress.
Research protocols for tanning studies typically employ 0.25-0.5mg MT-2 daily for 10-14 days. Lower doses (0.25mg) produce gradual, natural-looking pigmentation suitable for fair-skinned subjects, while higher doses (0.5mg) generate more rapid, intense darkening. Researchers should implement appropriate washout periods (3-6 months) between study cycles, as melanin persists in skin for extended periods after peptide discontinuation.
The photoprotective effects of MT-2 extend beyond simple melanin production. Research indicates that melanocortin receptor activation also enhances DNA repair mechanisms, reduces UV-induced inflammation, and modulates immune responses in skin. These pleiotropic effects suggest that MT-2’s benefits for photosensitivity disorders may involve multiple protective pathways beyond melanogenesis alone.
Clinical research has explored MT-2 for conditions including polymorphic light eruption (PLE), solar urticaria, and erythropoietic protoporphyria (EPP). While Melanotan 1 has received FDA approval for EPP, MT-2 research continues to investigate its potential for broader photosensitivity applications. The peptide’s ability to provide photoprotection without UV exposure makes it particularly valuable for subjects who cannot tolerate sun exposure for medical reasons.
One of Melanotan 2’s most remarkable and well-documented effects involves enhancement of sexual function through MC4R activation. This application has generated substantial research interest, with multiple clinical trials demonstrating MT-2’s effectiveness for erectile dysfunction and libido enhancement in both male and female subjects. The peptide’s mechanism differs fundamentally from phosphodiesterase-5 (PDE5) inhibitors like sildenafil, offering researchers an alternative pathway for studying sexual dysfunction.
The melanocortin system plays a crucial role in regulating sexual behavior through central nervous system pathways. MC4R is highly expressed in hypothalamic nuclei including the paraventricular nucleus (PVN), a key integration center for sexual function. When MT-2 activates MC4R in the PVN, it triggers a cascade of neural events that enhance sexual arousal, desire, and erectile response.
Research indicates that MC4R activation in the PVN stimulates release of oxytocin, a neuropeptide critical for sexual behavior and pair bonding. Oxytocin neurons project to the spinal cord, where they facilitate erectile reflexes through parasympathetic activation. This central mechanism explains why MT-2 produces spontaneous erections independent of sexual stimulation, distinguishing it from PDE5 inhibitors that require sexual arousal to be effective.
Additionally, MC4R activation influences dopaminergic pathways in the mesolimbic reward system. Dopamine plays a central role in sexual motivation and desire, with increased dopaminergic signaling enhancing libido and sexual interest. MT-2’s effects on dopamine neurotransmission contribute to its pro-sexual effects, particularly the increased sexual desire reported by research subjects.
Clinical studies have demonstrated impressive results for MT-2 in erectile dysfunction research. In a landmark study by Wessells et al., 85% of male subjects with erectile dysfunction reported improved erections after MT-2 administration. The average erection duration was 41 minutes, and 68% of subjects reported increased sexual desire. Importantly, MT-2 was effective across multiple ED etiologies, including psychogenic, organic, and mixed causes.
The peptide’s effectiveness for psychogenic erectile dysfunction is particularly noteworthy. Many ED cases involve psychological factors like performance anxiety, stress, or depression rather than vascular or neurological pathology. PDE5 inhibitors address the physiological component but don’t directly target psychological factors. MT-2’s central mechanism, working through brain pathways that regulate sexual motivation and arousal, makes it uniquely suited for psychogenic ED research.
Research protocols for sexual function studies typically employ higher MT-2 doses than tanning research. The standard protocol involves 1-2mg per dose (approximately 0.025mg/kg for a 175lb subject), administered as needed with minimum 48-hour intervals between doses. Effects typically manifest within 2-4 hours and persist for 6-8 hours. Subjects often report spontaneous erections and increased sexual thoughts even without deliberate sexual stimulation.
Female sexual function research has also explored MT-2’s potential. Studies demonstrate that the peptide enhances proceptive sexual behaviors in female subjects, suggesting increased sexual desire and receptivity. The melanocortin system’s role in female sexual function appears similar to males, involving hypothalamic pathways that regulate arousal and motivation. A metabolite of MT-2 called bremelanotide (PT-141) has received FDA approval for treating hypoactive sexual desire disorder (HSDD) in premenopausal women, validating the melanocortin approach to female sexual dysfunction.
The side effect profile for sexual function research differs somewhat from tanning protocols. At the higher doses used for ED research (1-2mg), subjects more frequently report nausea (41%), stretching/yawning (56%), and flushing. These effects are generally mild and transient, resolving within 2-4 hours. Rare but serious side effects include priapism (prolonged, painful erections lasting >4 hours), which has been reported in case studies. Researchers should educate subjects about priapism recognition and management.
An important consideration for sexual function research involves the peptide’s effects on both physiological and psychological components of sexual response. MT-2 doesn’t simply facilitate erections mechanically; it enhances the entire sexual experience including desire, arousal, and satisfaction. This holistic effect makes MT-2 valuable for research examining the complex interplay between physiological and psychological factors in sexual function.
The peptide’s mechanism also offers insights into the neurobiology of sexual behavior. By studying how MC4R activation influences sexual function, researchers can better understand the brain circuits and neurotransmitter systems that regulate human sexuality. This knowledge has implications beyond ED treatment, potentially informing approaches to other sexual disorders including premature ejaculation, delayed ejaculation, and disorders of sexual desire.
Beyond tanning and sexual function, Melanotan 2 demonstrates significant effects on appetite regulation and metabolic homeostasis through activation of MC3R and MC4R in hypothalamic feeding centers. This application has generated increasing research interest as obesity rates continue rising globally and researchers seek novel approaches to understanding and managing energy balance.
The melanocortin system serves as a critical regulator of energy homeostasis, integrating signals about nutritional status and modulating feeding behavior accordingly. MC3R and MC4R are expressed in hypothalamic nuclei including the arcuate nucleus (ARC), paraventricular nucleus (PVN), and lateral hypothalamic area (LHA), regions that control appetite, satiety, and energy expenditure.
When MT-2 activates MC3R and MC4R in these regions, it produces anorexigenic (appetite-suppressing) effects through multiple mechanisms. First, the peptide enhances activity of pro-opiomelanocortin (POMC) neurons in the arcuate nucleus, which release α-MSH and other melanocortin peptides that suppress appetite. Second, MT-2 inhibits neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons, which normally stimulate feeding. This dual action creates a powerful appetite-suppressing signal.
Research demonstrates that MT-2 reduces food intake in a dose-dependent manner. Animal studies show that melanocortin receptor activation decreases meal size, increases inter-meal intervals, and reduces overall caloric consumption. The effect appears selective for certain macronutrients, with some research suggesting preferential reduction in fat intake over carbohydrate or protein consumption.
Beyond simple appetite suppression, MT-2 influences metabolic rate and energy expenditure. MC4R activation increases sympathetic nervous system activity, elevating heart rate, blood pressure, and thermogenesis. This increased energy expenditure contributes to weight loss independent of reduced food intake. Studies in animal models demonstrate that melanocortin agonists produce greater weight loss than would be predicted from caloric restriction alone, suggesting enhanced metabolic rate.
The peptide also affects substrate utilization and fat oxidation. Research indicates that MC4R activation promotes lipolysis (fat breakdown) and increases fatty acid oxidation, shifting metabolism toward fat utilization. This metabolic shift may contribute to the body composition changes observed in weight loss studies, with preferential loss of fat mass over lean mass.
Clinical research on MT-2’s metabolic effects remains limited compared to tanning and sexual function applications. However, available data suggest significant potential. Studies report that subjects administered MT-2 experience reduced appetite, decreased food cravings, and modest weight loss. The appetite suppression appears most pronounced during the first 1-2 weeks of administration, with some tolerance developing over time.
Research protocols for metabolic studies typically employ moderate MT-2 doses (0.5-1mg daily) for 2-4 weeks. This dosing range produces appetite suppression without excessive side effects. Researchers should monitor food intake, body weight, body composition, and metabolic parameters including resting energy expenditure, respiratory quotient, and substrate oxidation rates.
An important consideration involves the relationship between MT-2’s multiple effects. The same doses that suppress appetite also produce tanning and sexual effects, making it challenging to isolate metabolic effects in research protocols. Researchers interested specifically in metabolic applications may need to account for these concurrent effects in experimental design and data interpretation.
The peptide’s effects on food preferences and eating behavior warrant further investigation. Some research suggests that melanocortin activation reduces hedonic eating (eating for pleasure) while preserving homeostatic eating (eating for energy needs). This selective effect on reward-driven consumption could have implications for understanding and treating binge eating disorders and food addiction.
MT-2’s metabolic effects also interact with its sexual function effects in interesting ways. Both appetite and sexual behavior are regulated by overlapping hypothalamic circuits, with some neurons responding to both feeding-related and sexual cues. The melanocortin system appears to coordinate these competing motivational states, potentially explaining why sexual arousal often suppresses appetite and vice versa.
Research on MT-2’s metabolic effects must consider potential safety concerns. The peptide’s effects on blood pressure and heart rate, mediated through sympathetic activation, require monitoring in metabolic studies. Additionally, the long-term effects of chronic melanocortin receptor activation on metabolic health remain incompletely understood, necessitating careful protocol design for extended studies.
Proper dosing represents a critical factor in Melanotan 2 research success. The peptide’s effects are highly dose-dependent, with different applications requiring distinct dosing strategies. Understanding evidence-based protocols ensures optimal results while minimizing side effects and maintaining subject safety.
Tanning Research Protocol:
Sexual Function Research Protocol:
Metabolic Research Protocol:
Reconstitution Instructions: Melanotan 2 is supplied as lyophilized powder requiring reconstitution before use. Follow these steps for proper preparation:
Dosage Calculations: For a 10mg vial reconstituted with 1mL bacteriostatic water:
For a 10mg vial reconstituted with 2mL bacteriostatic water:
Administration Technique:
Timing Considerations:
Dose Titration: Researchers should consider gradual dose escalation, particularly for subjects new to MT-2:
Special Populations:
While Melanotan 2 demonstrates significant effects as a standalone research peptide, strategic combinations with complementary compounds can enhance specific research outcomes or provide synergistic benefits. Understanding evidence-based stacking protocols allows researchers to design sophisticated multi-peptide studies that explore integrated physiological responses.
MT-2 + PT-141 (Bremelanotide) for Sexual Function Research: PT-141 is a metabolite of MT-2 that has received FDA approval for female hypoactive sexual desire disorder. Combining MT-2 with PT-141 may provide enhanced sexual function effects through complementary mechanisms. PT-141 demonstrates higher selectivity for MC4R over MC1R, potentially providing sexual benefits with less tanning effect.
Protocol:
MT-2 + BPC-157 for Skin Health Research: BPC-157 demonstrates wound healing and tissue repair properties that may complement MT-2’s pigmentation effects. This combination could be valuable for research on skin recovery, scar healing, or dermatological conditions.
Protocol:
MT-2 + Ipamorelin for Body Composition Research: Ipamorelin stimulates growth hormone release, promoting fat loss and lean mass preservation. Combined with MT-2’s appetite suppression and metabolic effects, this stack may enhance body composition changes.
Protocol:
MT-2 + CJC-1295 for Enhanced Metabolic Research: CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that elevates growth hormone and IGF-1 levels. Combined with MT-2, this stack provides comprehensive metabolic modulation.
Protocol:
MT-2 + Tesamorelin for Visceral Fat Research: Tesamorelin specifically targets visceral adipose tissue, the metabolically harmful fat surrounding internal organs. Combined with MT-2’s general appetite suppression, this stack may provide enhanced fat loss.
Protocol:
MT-2 + TB-500 for Recovery and Skin Health: TB-500 promotes tissue repair, angiogenesis, and wound healing. Combined with MT-2’s photoprotective effects, this stack may benefit skin health research.
Protocol:
Important Stacking Considerations:
Understanding Melanotan 2’s safety profile is essential for responsible research conduct. While the peptide has been studied in numerous clinical trials, researchers must remain aware of potential adverse effects and implement appropriate monitoring and risk mitigation strategies.
Common Side Effects (Frequency >10%):
Nausea (41%): The most frequently reported side effect, typically occurring 30-60 minutes post-injection and lasting 1-2 hours. Nausea appears dose-dependent and often diminishes with repeated administration as tolerance develops.
Mitigation Strategies:
Stretching and Yawning (56%): Unusual spontaneous stretching and yawning episodes, likely related to hypothalamic effects. Generally harmless but can be socially awkward.
Mitigation Strategies:
Flushing (20-30%): Facial redness and warmth, similar to hot flashes. Related to vasodilation from melanocortin receptor activation.
Mitigation Strategies:
Decreased Appetite (15-25%): Reduced hunger and food cravings, particularly at higher doses. While desired for metabolic research, may be problematic for subjects requiring adequate nutrition.
Mitigation Strategies:
Uncommon Side Effects (Frequency 1-10%):
Increased Libido and Spontaneous Erections: Enhanced sexual desire and spontaneous erections, particularly at doses ≥1mg. While often desired for sexual function research, can be uncomfortable or socially inappropriate.
Mitigation Strategies:
Darkening of Existing Moles and Freckles: MT-2 stimulates melanin production in all melanocytes, including those in moles and freckles. Existing pigmented lesions may darken noticeably.
Mitigation Strategies:
Facial Flushing and Increased Skin Sensitivity: Some subjects report increased skin sensitivity, particularly to touch and temperature.
Mitigation Strategies:
Rare but Serious Side Effects (Frequency <1%):
Priapism (Prolonged Erection): Case reports document priapism (erections lasting >4 hours) in subjects using MT-2 for sexual function. This is a medical emergency requiring immediate intervention to prevent permanent damage.
Risk Factors:
Management:
Melanoma and Skin Cancer Concerns: Some case reports have linked prolonged MT-2 use (>1 month) combined with UV exposure to rapidly changing moles or melanoma development. Causation remains unproven, but the association warrants caution.
Risk Factors:
Risk Mitigation:
Cardiovascular Effects: MT-2 activates sympathetic nervous system, potentially increasing heart rate and blood pressure. While generally mild, this could be problematic for subjects with cardiovascular disease.
Risk Factors:
Monitoring:
Contraindications:
Melanotan 2 research should exclude subjects with:
Drug Interactions:
PDE5 Inhibitors (Sildenafil, Tadalafil): Combining MT-2 with PDE5 inhibitors may increase priapism risk. If studying combination effects, use lowest effective doses and provide clear safety instructions.
Stimulants and Sympathomimetics: Concurrent use may potentiate cardiovascular effects. Monitor blood pressure and heart rate carefully.
Immunosuppressants: Melanocortin receptors play roles in immune function. Theoretical concerns exist about interactions with immunosuppressive medications, though clinical significance remains unclear.
Long-Term Safety Considerations:
Most MT-2 research involves short-term administration (2-4 weeks). Long-term safety data (>3 months continuous use) is limited. Researchers planning extended studies should:
Quality and Purity Considerations:
Peptide quality significantly impacts safety. Low-purity peptides may contain contaminants, degradation products, or incorrect amino acid sequences that increase adverse effect risk. PrymaLab’s commitment to 99%+ purity with third-party verification ensures researchers work with pharmaceutical-grade material, minimizing contamination-related risks.
Research integrity depends fundamentally on peptide quality. Impure, degraded, or incorrectly synthesized peptides produce unreliable results, waste research resources, and potentially compromise subject safety. PrymaLab’s rigorous quality assurance program ensures every Melanotan 2 vial meets pharmaceutical-grade standards.
Third-Party Laboratory Testing: Every batch of PrymaLab Melanotan 2 undergoes comprehensive analysis by independent, ISO-certified laboratories. This third-party verification provides unbiased confirmation of quality, eliminating potential conflicts of interest inherent in vendor self-testing.
High-Performance Liquid Chromatography (HPLC): HPLC represents the gold standard for peptide purity analysis. This technique separates peptide components based on their chemical properties, allowing precise quantification of the target peptide and identification of impurities.
Our MT-2 consistently achieves ≥99% purity by HPLC, meaning that 99% or more of the material in each vial is the correct Melanotan 2 peptide. The remaining <1% consists of minor synthesis byproducts, salts, or residual solvents at levels well below safety thresholds.
Mass Spectrometry (MS): Mass spectrometry confirms molecular weight and amino acid sequence, verifying that the peptide is indeed Melanotan 2 and not a related compound or synthesis error. This technique detects even single amino acid substitutions that could alter peptide activity.
Amino Acid Analysis: Quantitative amino acid analysis confirms the correct amino acid composition and ratios, providing additional verification of peptide identity and purity.
Endotoxin Testing: Bacterial endotoxins can contaminate peptides during synthesis or handling, potentially causing fever, inflammation, or other adverse effects. We test every batch for endotoxins using the Limulus Amebocyte Lysate (LAL) assay, ensuring levels remain below 1 EU/mg (well below the 5 EU/mg FDA limit for injectable products).
Sterility Testing: While lyophilized peptides are not sterile products, we test for bacterial and fungal contamination to ensure product safety. Reconstitution with bacteriostatic water provides antimicrobial protection during storage and use.
Certificate of Analysis (COA): Every PrymaLab Melanotan 2 purchase includes a Certificate of Analysis documenting:
Storage and Stability: Proper storage maintains peptide quality throughout its shelf life:
Visual Inspection: Before use, inspect peptide vials for:
The research peptide market contains numerous vendors with varying quality standards, customer service, and reliability. Selecting a trusted supplier is crucial for research success. Here’s why PrymaLab stands out as the premier choice for Melanotan 2 research.
Uncompromising Quality Standards: PrymaLab maintains pharmaceutical-grade quality standards typically reserved for clinical-grade materials. Our 99%+ purity specification exceeds industry norms, ensuring researchers work with the highest quality peptides available. Third-party testing by independent laboratories provides unbiased verification, giving researchers confidence in product quality.
Transparent Testing Documentation: We provide complete Certificates of Analysis with every order, including detailed HPLC chromatograms, mass spectrometry data, and endotoxin test results. This transparency allows researchers to verify quality independently and maintain proper documentation for institutional requirements.
Competitive Pricing: Despite our premium quality standards “As it turns out stacking proteins together isn’t quite as expensive as some would lead you to believe. lol”, PrymaLab offers highly competitive pricing. Our Melanotan 2 10mg vials retail for $33.99, providing exceptional value compared to competitors charging $50-80 for a inferior product. Volume discounts are available for larger orders, further reducing per-vial costs for extensive research programs.
Fast, Reliable Shipping: We understand that research timelines are critical. Orders ship within 24 hours of payment confirmation, with all domestic deliveries arriving within 1-3 business days. International shipping is available to most countries, with tracking provided for all order and delivery within 2-5 business days in 95% of countries.
Secure Payment Options: PrymaLab accepts multiple payment methods including:
All transactions use SSL encryption to protect financial information.
Exceptional Customer Support: Our knowledgeable customer support team responds to inquiries within 24 hours (typically much faster). Whether you need help with product selection, dosing protocols, reconstitution instructions, or order tracking, we’re here to assist. Support is available via email, phone, and live chat.
Educational Resources: PrymaLab provides comprehensive educational content including:
Institutional Accounts: We work with research institutions, universities, and laboratories worldwide. Institutional accounts receive:
Satisfaction Guarantee: We stand behind our products with a satisfaction guarantee. If you’re not completely satisfied with your purchase, contact us within 30 days for resolution. While we cannot accept returns of peptides due to their temperature-sensitive nature, we’ll work with you to address any quality concerns.
Regulatory Compliance: All PrymaLab peptides are sold exclusively for research purposes and comply with applicable regulations. We do not sell peptides for human consumption or medical use. Proper documentation and intended use verification may be required for certain orders.
Comprehensive peptide research often requires multiple compounds and supplies. PrymaLab offers a complete range of research peptides and essential materials to support your work.
Complementary Tanning Peptides:
Sexual Function Research Peptides:
Growth Hormone Peptides:
Tissue Repair and Recovery Peptides:
Essential Research Supplies:
Research Tools:
Browse Complete Catalog:
1. What is Melanotan 2 and how does it work?
Melanotan 2 is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH). It works by activating melanocortin receptors (MC1R, MC3R, MC4R) throughout the body. MC1R activation in melanocytes stimulates melanin production, causing skin darkening. MC4R activation in the hypothalamus enhances sexual function and erectile response. MC3R and MC4R activation in feeding centers suppresses appetite and increases metabolism. This multi-receptor activity makes MT-2 valuable for diverse research applications including tanning, sexual dysfunction, and metabolic studies.
2. How does Melanotan 2 differ from Melanotan 1?
The key differences are: (1) Structure – MT-2 is a cyclic heptapeptide (7 amino acids in a ring) while MT-1 is a linear tetradecapeptide (13 amino acids in a chain). (2) Receptor selectivity – MT-2 activates multiple melanocortin receptors (MC1R, MC3R, MC4R) while MT-1 primarily targets MC1R. (3) Effects – MT-2 produces tanning, sexual enhancement, and appetite suppression; MT-1 primarily produces tanning and photoprotection. (4) Dosing – MT-2 requires once-daily dosing; MT-1 typically requires twice-daily dosing. (5) Regulatory status – MT-1 is FDA-approved (Scenesse) for erythropoietic protoporphyria; MT-2 is research-only.
3. What is the proper dosage for Melanotan 2 research?
Dosing depends on research application: For tanning research, use 0.25-0.5mg daily for 10-14 days. For sexual function research, use 1-2mg per dose as needed with minimum 48-hour intervals between doses. For metabolic research, use 0.5-1mg daily for 2-4 weeks. Always start at the lower end of the dosing range to assess tolerance, then titrate upward if needed. Implement appropriate washout periods (3-6 months for tanning research, 4-8 weeks for metabolic research) between study cycles.
4. How do I reconstitute and store Melanotan 2?
Reconstitute by adding 1-2mL bacteriostatic water to the 10mg vial. Inject water slowly against the vial wall, then gently swirl (don’t shake) to dissolve. Refrigerate for 2-4 hours until completely dissolved. Store lyophilized powder at -20°C (freezer) for up to 2 years. Store reconstituted solution at 2-8°C (refrigerator) for up to 30 days. Protect from light and avoid repeated freeze-thaw cycles. Use sterile technique when handling to prevent contamination.
5. What are the most common side effects of Melanotan 2?
The most common side effects are nausea (41%), stretching/yawning (56%), flushing (20-30%), and decreased appetite (15-25%). These effects are generally mild and transient, resolving within 1-2 hours. Less common effects include increased libido, spontaneous erections, and darkening of existing moles. Rare but serious effects include priapism (prolonged erections >4 hours) and potential melanoma risk with prolonged use combined with UV exposure. Most side effects can be managed through dose adjustment, timing optimization, and supportive measures.
6. Can Melanotan 2 be combined with other peptides?
Yes, MT-2 can be strategically combined with complementary peptides for enhanced research outcomes. Common combinations include: MT-2 + Ipamorelin for body composition research, MT-2 + BPC-157 for skin health studies, MT-2 + CJC-1295 for metabolic research, and MT-2 + TB-500 for recovery and tissue repair. When stacking peptides, start with lower doses of each compound to assess combined tolerability, then titrate upward as needed. Maintain detailed documentation of all peptides used, doses, timing, and observed effects.
7. How long does it take to see results from Melanotan 2?
Results timeline varies by application: For tanning, initial pigmentation becomes visible within 3-5 days, with progressive darkening over 10-14 days. For sexual function, effects typically manifest within 2-4 hours of administration and persist for 6-8 hours. For appetite suppression, effects begin within hours of first dose and are most pronounced during the first 1-2 weeks (some tolerance develops over time). For metabolic effects, measurable changes in body weight and composition typically require 2-4 weeks of consistent administration.
8. Is Melanotan 2 safe for long-term research?
Most MT-2 research involves short-term administration (2-4 weeks). Long-term safety data (>3 months continuous use) is limited. Some case reports have linked prolonged MT-2 use (>1 month) combined with UV exposure to melanoma development, though causation remains unproven. For extended research, implement regular safety monitoring including monthly assessments, dermatological examinations every 3 months, cardiovascular parameter monitoring, and periodic washout periods (1-2 weeks every 2-3 months). Limit study duration to ≤14 days with extended washout periods when possible.
9. What makes PrymaLab’s Melanotan 2 superior to competitors?
PrymaLab Melanotan 2 offers: (1) Pharmaceutical-grade 99%+ purity verified by third-party testing, (2) Complete Certificates of Analysis with every order including HPLC, mass spectrometry, and endotoxin data, (3) Competitive pricing at $33.99 per 10mg vial, (4) Fast shipping within 24 hours of payment, (5) Multiple secure payment options, (6) Exceptional customer support responding within 24 hours, (7) Comprehensive educational resources and dosing protocols, (8) Satisfaction guarantee and quality commitment. Our rigorous quality standards ensure researchers work with the highest quality peptides available.
10. Who should not use Melanotan 2 in research?
Exclude subjects with: Personal or family history of melanoma or skin cancer, pregnancy or breastfeeding, age <18 years, uncontrolled hypertension or cardiovascular disease, history of priapism, numerous atypical moles or dysplastic nevi, and photosensitivity disorders requiring medical management. Use caution in subjects with cardiovascular disease, concurrent stimulant use, or those taking PDE5 inhibitors. Always screen subjects carefully and implement appropriate monitoring protocols to ensure research safety.
Melanotan 2 is sold exclusively as a research chemical for scientific and educational purposes. This product is NOT intended for human consumption, medical use, or any application involving administration to humans or animals outside of controlled research settings.
Purchasers must be 21 years of age or older. By purchasing this product, you confirm that you meet this age requirement and will use the product only for legitimate research purposes.
This product is intended for use by qualified researchers, scientists, and healthcare professionals conducting legitimate research. Proper training in peptide handling, reconstitution, and research protocols is required.
Melanotan 2 is not a medication, drug, or therapeutic agent. It has not been evaluated or approved by the FDA for the treatment, cure, or prevention of any disease or medical condition. Any statements regarding research applications are based on published scientific literature and do not constitute medical claims.
Melanotan 2 is not approved by the FDA for human use. While Melanotan 1 (afamelanotide) has received FDA approval as Scenesse for erythropoietic protoporphyria, Melanotan 2 remains an investigational compound restricted to research applications.
Users assume all responsibility for proper handling, storage, and use of this product. PrymaLab is not liable for any adverse effects, injuries, or damages resulting from improper use, misuse, or use outside of controlled research settings. Researchers must implement appropriate safety protocols and obtain necessary institutional approvals before conducting research.
Anyone considering research involving Melanotan 2 should consult with qualified healthcare professionals, institutional review boards, and regulatory authorities as appropriate. This is particularly important for research involving human subjects, which requires proper ethical approval and informed consent procedures.
Peptide regulations vary by country. International purchasers are responsible for ensuring compliance with their local laws and regulations regarding peptide importation and research use. PrymaLab is not responsible for shipments seized by customs or violations of local regulations.
While we maintain rigorous quality control standards, PrymaLab makes no warranties regarding the suitability of this product for any particular research application. Researchers are responsible for validating product performance in their specific experimental systems.
| Weight | 0.1 lbs |
|---|---|
| Dimensions | N/A |
Only logged in customers who have purchased this product may leave a review.
support@prymalab.net info@prymalab.net
30 Day return window. Satisfaction guaranteed or your money back.
All orders over %150 in value will receive free shipping.
1 review for MT-2 (Melanotan 2 Acetate) 10mg